Remix Therapeutics, a biotechnology company dedicated to discovering small molecule treatments to target the root causes of illness, is proud to welcome Robert Gagnon as its new Chief Financial Officer. With his expertise in financial leadership, Robert brings an invaluable addition to Remix’s team as it continues its mission to develop innovative therapies for patients.
We are thrilled to welcome Rob to Remix Therapeutics as the new CFO! His deep knowledge of the life science industry and financial acumen make him the perfect fit for this role. Rob’s addition to our leadership team, which is comprised of experienced industry veterans, will be a major asset as we continue to develop and deploy our REMaster technology platform to fight diseases with unmet need. His impressive track record in biopharmaceutical finance and ability to grow organizations will be integral to our success.
I am thrilled to join Remix, as we have a remarkable chance to revolutionize the treatment of various diseases with our novel platform that modulates RNA processing to target the core of these diseases. I’m eager to work with my colleagues and make Remix a top biopharmaceutical company that transforms the way we approach treatment.
Mr. Gagnon brings an impressive array of financial and commercial acumen with over two decades of experience in global finance operations. Recently, he served as Chief Financial Officer and Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund.
Moreover, he has held executive and financial leadership roles at various public and private biotechnology companies, such as Verastem Oncology, Harvard Bioscience, Inc., Clean Harbors, Inc., and Biogen Idec, Inc. His professional journey also includes senior positions at Deloitte & Touche, LLP, and Price Waterhouse Coopers, LLP. Mr. Gagnon holds an M.B.A. from the MIT Sloan School of Management and a B.A. in Accounting from Bentley College.
Mr. Gagnon is an esteemed member of the Board of Directors at Verastem Oncology and Purple Biotech, where he plays a key role in driving the success of both companies. With a wealth of experience in the healthcare industry, he is a valuable asset to both organizations and is helping to shape their future.
About Remix Therapeutics
Remix Therapeutics is revolutionizing the way we treat disease. Utilizing their innovative REMaster technology platform, they are able to identify and modulate gene expression by reprogramming RNA processing.
This cutting-edge approach has the potential to directly target the source of diseases, potentially correcting, enhancing, or eliminating the gene message. A remarkable new way to tackle medical ailments, Remix Therapeutics is paving the way for a brighter tomorrow.